Canary Speech Secures $13 Million in Series A
Canary Speech, a Provo, Utah-based AI-powered voice biomarker health tech company, has secured $13 million in Series A funding.
Canary Speech, a Provo, Utah-based AI-powered voice biomarker health tech company, has secured $13 million in Series A funding.
Investors
The round was led by Cortes Capital, LLC, with participation from Sorenson Communications, LLC, SMK (Japan), and Hackensack Meridian Health.
Cortes Capital is a private equity firm based in Oklahoma City, Oklahoma. Cortes Capital is an investment arm of Love's private equity.
Canary Speech Use of Funds
The company will use the funding to expand the team and accelerate the company’s growth and technology development.
About Canary Speech
Founded by Henty O'Connell and Jeff Adams, Canary Speech is an AI voice tech company that uses real-time patented vocal analysis to screen for mental health and neurological disorders. Its vocal biomarker technology captures and analyzes speech data within seconds to identify irregularities in behavioral and cognitive changes before current clinical screening standards or noticeable symptoms for invisible illnesses like anxiety, depression, and dementia. Based in Utah, the company advances speech and language applications for health systems, payers, and pharmaceutical markets.
Funding Details
Company: Canary Speech, Inc.
Raised: $13.0M
Round: Series A
Funding Month: June 2024
Lead Investors: Cortes Capital, LLC
Additional Investors: Sorenson Communications, LLC, SMK (Japan), Hackensack Meridian Health
Company Website: https://canaryspeech.com/
Software Category: AI Speech Analysis
